3 news items
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
ABBV
ACAD
BAYRY
24 May 24
, a spokesperson for Cencora, confirmed these details in an email to TechCrunch.
This incident is the latest in a series of cyberattacks targeting
AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also Met
ABBV
18 Apr 24
percent of the upadacitinib 15 mg group and 11 percent of the placebo group.1 Overall, the proportions of patients with incidence of malignancy
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
ABBV
18 Apr 24
with incidence of malignancy excluding non-melanoma skin cancer and adjudicated venous thromboembolic events (VTEs) were balanced across both the upadacitinib
- Prev
- 1
- Next